These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 2969953)
21. A study on the effect and tolerance of lisuride on Parkinson's disease. Bayülkem K; Erişir K; Tuncel A; Bayülkem B Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174 [TBL] [Abstract][Full Text] [Related]
26. [Oral lisuride in Parkinson's disease]. Obeso JA; Luquin MR; Martínez Lage JM Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822 [No Abstract] [Full Text] [Related]
27. Lisuride and pergolide in Parkinson's disease. Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769 [No Abstract] [Full Text] [Related]
28. [Orally administered lisuride in the treatment of complex fluctuations of motion in Parkinson disease]. Luquín MR; Obeso JA; Vaamonde J; Martínez Lage JM Neurologia; 1989 Sep; 4(7):229-32. PubMed ID: 2638588 [TBL] [Abstract][Full Text] [Related]
29. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. Stocchi F; Ruggieri S; Brughitta G; Agnoli A J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872 [TBL] [Abstract][Full Text] [Related]
30. [Lisuride in the combination treatment of Parkinson disease]. Jellinger K Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099 [TBL] [Abstract][Full Text] [Related]
31. Continuous dopaminergic stimulation in Parkinson's disease. Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922 [TBL] [Abstract][Full Text] [Related]
32. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies. LeWitt PA; Burns RS; Calne DB Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586 [TBL] [Abstract][Full Text] [Related]
34. Pergolide and lisuride for Parkinson's disease. Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856 [No Abstract] [Full Text] [Related]
35. Pharmacokinetics of lisuride after subcutaneous infusion. Krause W; Nieuweboer B; Ruggieri S; Stocchi F; Suchy I J Neural Transm Suppl; 1988; 27():71-4. PubMed ID: 3165439 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic effect of lisuride in advanced Parkinson's disease. Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126 [TBL] [Abstract][Full Text] [Related]
37. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Rinne UK Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639 [TBL] [Abstract][Full Text] [Related]
38. Continuous dopaminergic stimulation: state of the art and outlook. Horowski R; Marsden CD; Obeso JA J Neural Transm Suppl; 1988; 27():249-52. PubMed ID: 3042911 [No Abstract] [Full Text] [Related]
39. Further studies with lisuride in Parkinson's disease. Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E Eur Neurol; 1983; 22(2):119-23. PubMed ID: 6341071 [TBL] [Abstract][Full Text] [Related]
40. Continuous dopaminergic stimulation in the management of complicated Parkinson's disease. Agnoli A; Stocchi F; Carta A; Antonini A; Bragoni M; Ruggieri SA Mt Sinai J Med; 1988 Jan; 55(1):62-6. PubMed ID: 3258057 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]